Immune Profiles Evolution Under Immunotherapy for Melanoma

Summary

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.

Eligibility

Inclusion Criteria:

* Patient aged ≥ 18 years;
* Totally resected stage III or IV melanoma totally resected, treated with a immune therapy (pembrolizumab or nivolumab ou other immune checkpoint inhibitors) as adjuvant treatment;
* Unresectable stage IIIC/D or IV metastatic melanoma, treated with immune therapy (pembrolizumab or nivolumab or immune checkpoint inhibitors) which should be associated by a radiotherapy ;
* Patient has been informed about the study and signed the consent;
* Affiliated to the French social security scheme.

Exclusion Criteria:

* Pregnant or breastfeeding woman;
* Patient refusal;
* Patient receiving a immunosuppressor;
* Undergo a general corticotherapy of \> 10 mg/kg/day since more than 7 days;
* Patient who participate to another blind interventional study receiving blinded treatment;
* Patient without any social protection by organization.

Conditions2

Browse More Trials